These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28285082)

  • 41. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.
    Majithia N; Rajkumar SV; Lacy MQ; Buadi FK; Dispenzieri A; Gertz MA; Hayman SR; Dingli D; Kapoor P; Hwa L; Lust JA; Russell SJ; Go RS; Kyle RA; Kumar SK
    Leukemia; 2016 Nov; 30(11):2208-2213. PubMed ID: 27211270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stem-cell transplantation for multiple myeloma in the era of novel drugs.
    Bensinger W
    J Clin Oncol; 2008 Jan; 26(3):480-92. PubMed ID: 18056678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current treatment options of T cell-associated immunotherapy in multiple myeloma.
    Liu H; Pan Y; Meng S; Zhang W; Zhou F
    Clin Exp Med; 2017 Nov; 17(4):431-439. PubMed ID: 28120217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
    Lenhoff S; Hjorth M; Turesson I; Westin J; Gimsing P; Wislöff F; Ahlberg L; Carlson K; Christiansen I; Dahl IM; Forsberg K; Brinch L; Hammerström J; Johnsen HE; Knudsen LM; Linder O; Mellqvist UH; Nesthus I; Nielsen JL;
    Haematologica; 2006 Sep; 91(9):1228-33. PubMed ID: 16956822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New approaches to management of multiple myeloma.
    Hájek R; Vásová I; Adam Z; Mayer J
    Acta Med Austriaca; 1996; 23(3):91-8. PubMed ID: 8798282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
    J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
    Siegel DS; Vij R; Jakubowiak AJ
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
    Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.
    Paviglianiti A; Xavier E; Ruggeri A; Ceballos P; Deconinck E; Cornelissen JJ; Nguyen-Quoc S; Maillard N; Sanz G; Rohrlich PS; Garderet L; Volt F; Rocha V; Kroeger N; Gluckman E; Fegueux N; Mohty M
    Haematologica; 2016 Sep; 101(9):1120-7. PubMed ID: 27229716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of multiple myeloma].
    Hájek R; Vásová I; Adam Z; Krejcí M; Mayer J; Krahulová M
    Vnitr Lek; 1996 May; 42(5):345-50. PubMed ID: 8768295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current role of immunotherapy in multiple myeloma.
    Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
    Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The role of biotherapy in multiple myeloma].
    Petrucci MT; Tafuri A; Mandelli F
    Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in immunotherapy in multiple myeloma.
    Boussi L; Niesvizky R
    Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
    Kuroda J
    Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.